Genmab — Marts 2015
-
The initial clinical studies with DR5-targeted antibodies indicate rather low initial clinical activities. Additional work such as antibody optimization, patient stratification based on certain biomarkers, or combination with other agents to synergize the activity of the antibody may be required to achieve better clinical outcomes.
-
Jan virker da også svært tilfreds "- Vi er glade for at tilføje dette spændende target og disse unikke DR5-antistoffer til vores stadigt voksende portefølje af prækliniske aktiver. Med denne transaktion opnår Genmab endnu en mulighed for at skabe potentielle næste-generations antistofbaserede lægemidler, som kan føre til nye måder at behandle cancer på, siger han i meddelelsen."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind